Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revelation Biosciences, Inc.

2.93
+0.17206.23%
Volume:44.15K
Turnover:130.09K
Market Cap:2.65M
PE:-0.02
High:3.11
Open:2.70
Low:2.70
Close:2.76
Loading ...

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Business Wire
·
06 Jan

Revelation Biosciences files to sell 14.22M shares of common stock for holders

TIPRANKS
·
13 Dec 2024

Revelation Biosciences Files for Shelf of up to 14.2 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
13 Dec 2024

Revelation Biosciences (REVB) Receives a Buy from Roth MKM

TIPRANKS
·
08 Dec 2024

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Business Wire
·
03 Dec 2024

REVB Gets FDA Go Ahead

Zacks Small Cap Research
·
02 Dec 2024

BRIEF-Revelation Biosciences Says Phase 1B Study In CKD Patients To Begin Early 2025

Reuters
·
02 Dec 2024

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini Ind

THOMSON REUTERS
·
02 Dec 2024

Revelation Biosciences Inc -Phase 1B Study in Ckd Patients to Begin Early 2025

THOMSON REUTERS
·
02 Dec 2024

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Business Wire
·
02 Dec 2024

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Business Wire
·
12 Nov 2024

REVB Results Set Stage for Future Growth

Zacks Small Cap Research
·
11 Nov 2024

Revelation Biosciences Inc expected to post a loss of $2.29 a share - Earnings Preview

Reuters
·
09 Nov 2024

Revelation Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
09 Nov 2024

Revelation Biosciences Q3 2024 GAAP EPS $(0.84) Beats $(2.84) Estimate

Benzinga
·
09 Nov 2024

BRIEF-Revelation Biosciences Inc. Q3 EPS USD -0.84

Reuters
·
09 Nov 2024